HORSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX:LCP), an emerging specialty pharmaceutical company focused on developing and commercializing differentiated versions of existing drugs in large therapeutic areas such as cardiovascular disease, organ transplantation and immunosuppression, including recently Food and Drug Administration approved LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia, announced today that Flemming Ornskov, President and Chief Executive Officer, is scheduled to give a company presentation at the UBS Global Life Sciences Conference on Tuesday, September 25, 2007 at 11:00 a.m. EDT (8:00 a.m. in San Francisco; 5:00 p.m. in Denmark) at the Grand Hyatt in New York City.
